Rite Aid customers in Western New York say their prescriptions were transferred without permission — and now they’re stuck in ...

Society / Forget Kennedy’s faux-populist, anti-science approach. The former FTC chair provides the real model of an ideal HHS ...

For CVS, Q2 earnings will be a critical inflection point. A miss could trigger a breakup or further decline, making the stock ...

The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it ...

Recent health news highlights various developments, including Trump's spending bill impacting insurance costs, a major acquisition in the bioscience sector, and GSK's efforts to expand RSV vaccine ...

Congress revives fight for coverage for Wegovy and other weight-loss drugs The Treat and Reduce Obesity Act bill could also ramp up federal support for obesity research efforts.

From a CVS subsidiary ordered to pay nearly $950 million in a false claims case to the Supreme Court upholding the ACA’s preventive coverage mandate, here are 12 healthcare industry lawsuits, ...

CVS Caremark stops coverage for Eli Lilly's weight loss drug Zepbound, citing high costs, while obesity specialists warn the decision disrupts patient treatment.

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there? Here's what to know.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...